InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes InMed CEO Eric A. Adams. “The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn process into larger vessels,” Adams said in a recent Vista Partners interview. “Considering our production methodology is being designed with the flexibility to produce multiple cannabinoids, it opens up many different markets and consumer categories. We continue to develop relationships with contract manufacturing organizations for scale-up of the process with the anticipation of commercializing the process shortly. Our immediate commercial plans are to become a B2B wholesale supplier of rare cannabinoids to companies that are seeking to integrate rare cannabinoids into their marketed products.”
To view the full article, visit https://cnw.fm/vukZA
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”), and is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.